We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Prostate Cancer Metastasis Requires Loss of E-Cadherin Activity

By LabMedica International staff writers
Posted on 18 Apr 2013
Cancer researchers have shown how the action of the transcription factor SPDEF (SAM Pointed Domain ETS transcription Factor) regulates E-Cadherin in prostate cancer cells and determines whether the prostate tumor will metastasize.

Cadherins (named for “calcium-dependent adhesion”) are a class of type-1 transmembrane proteins. More...
They play important roles in cell adhesion, ensuring that cells within tissues are bound together. They are dependent on calcium (Ca2+) ions to function, hence their name. It has been observed that cells containing a specific cadherin subtype tend to cluster together to the exclusion of other types, both in cell culture and during development. Loss of E-cadherin function or expression has been implicated in cancer progression and metastasis. E-cadherin down regulation decreases the strength of cellular adhesion within a tissue, resulting in an increase in cellular motility. This in turn may allow cancer cells to cross the basement membrane and invade surrounding tissues.

The SPDEF protein belongs to the ETS family of transcription factors. It is highly expressed in prostate epithelial cells and functions as an androgen-independent transactivator of prostate-specific antigen (PSA) promoter.

Investigators at the University of Colorado Cancer Center (Denver, USA) had shown previously that SPDEF inhibited prostate cancer metastasis in vitro and in vivo. In the present study, they evaluated the relationship between SPDEF and E-Cadherin expression in an effort to better understand the mechanism of action of SPDEF in prostate tumor-cell invasion and metastasis.

Results published in the February 28, 2013, online edition of the Journal of Biological Chemistry demonstrated a direct correlation between expression of E-Cadherin and SPDEF in prostate cancer cells and showed that modulation of E-Cadherin and SPDEF had similar effects on cell migration and invasion. In addition, short interfering RNA (siRNA) mediated knockdown of E-Cadherin was sufficient to block the effects of SPDEF on cell migration and invasion. Stable forced expression of SPDEF resulted in increased expression of E-Cadherin, while down regulation of SPDEF decreased E-Cadherin expression. SPDEF expression was not regulated by E-Cadherin.

A chromatin immuno-precipitation and luciferase reporter assay revealed that SPDEF occupied the E-Cadherin promoter site and acted as a direct transcriptional inducer of E-Cadherin in prostate cancer cells.

“When E-Cadherin is lost, cells become rogue: they can detach from their surrounding tissues, move effortlessly through the circulatory system, grow and attach at new sites,” said senior author Dr. Hari Koul, professor of urology at the University of Colorado Cancer Center. “In prostate tumors that had lost E-Cadherin, we put in SPDEF and the tumors once again expressed E-Cadherin. They were once again anchored in place and unable to metastasize. We can make these rogue cells back into epithelial-like cells and these epithelial cells stay anchored and lose the ability to migrate.”

“These studies paint a pretty compelling picture of SPDEF working in part through the modulation of E-Cadherin to inhibit prostate cancer metastasis,” said Dr. Koul. “To the best of our knowledge these are the first studies demonstrating the requirement of SPDEF for expression of E-Cadherin. This could be a real landmark. We see a prerequisite for metastasis and now we have a very clear picture of how to remove this necessary condition for the most dangerous behavior of prostate cancer.”

Related Links:

University of Colorado Cancer Center



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.